Physician profile
John E Legarreta
NPI 1629395892
$9,331.91
in general payments reported to CMS, 2019-2025
27 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $465 · 2021: $819 · 2022: $1,098 · 2023: $1,632 · 2024: $1,750 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,970 · Consulting Fee: $323 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.44 |
| Consulting Fee | $322.50 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,603.41 | 2019-2025 | Unity, Rocklatan, Centurion |
| Abbvie INC. | $876.36 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $713.71 | 2023-2025 | Syfovre |
| Biotissue Holdings INC. | $712.33 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $593.41 | 2019-2025 | Cequa, Xelpros |
| Alimera Sciences, INC. | $535.32 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $452.77 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $448.58 | 2019-2023 | |
| Allergan, INC. | $398.06 | 2019-2022 | |
| Sight Sciences, INC. | $352.56 | 2020-2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $318.41 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $251.03 | 2019-2024 | Vabysmo |
| Harrow Eye, LLC | $240.11 | 2024-2025 | Iheezo, Vevye, Triesence |
| Oyster Point Pharma, INC. | $200.15 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $123.84 | 2022-2023 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $118.61 | 2019-2021 | |
| Astellas Pharma US INC | $85.85 | 2023-2024 | Izervay |
| Amgen INC. | $68.52 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.86 | 2020 | |
| Ocular Therapeutix, INC. | $45.36 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $27.47 | 2021 | |
| Coherus Oncology, INC. | $23.98 | 2023 | |
| Sandoz INC. | $22.87 | 2024 | Cimerli |
| Iridex Corporation | $22.62 | 2019 | |
| Dompe US, INC. | $18.66 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $17.06 | 2023 | Tecnis Simplicity |
| Shire North American Group INC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Legarreta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.